Chiesi UK and Ireland, in collaboration with Health Innovation Manchester, has announced the launch of the Improving Outcomes in Respiratory across Greater Manchester (MISSON) project. This initiative will introduce the clinically validated LungHealth software in up to 150 GP practices across the region over a two-year period.

基耶西英国和爱尔兰与曼彻斯特健康创新公司合作，宣布启动大曼彻斯特呼吸改善项目（MISSON）。该倡议将在两年内在该地区多达150个全科医生实践中引入经过临床验证的LungHealth软件。

The software utilizes existing digital technology, incorporating embedded algorithms based on national and international guidelines alongside patients’ medical records, to facilitate computer-guided consultations for annual reviews of asthma and Chronic Obstructive Pulmonary Disease (COPD). These consultations can be conducted either remotely or face-to-face..

该软件利用现有的数字技术，结合基于国家和国际指南的嵌入式算法以及患者的病历，以促进计算机指导的哮喘和慢性阻塞性肺病（COPD）年度评估咨询。这些咨询可以远程进行，也可以面对面进行。。

The MISSON project represents the largest regional implementation of LungHealth software in the UK. Its primary goal is to assess whether this technology can enhance the quality, effectiveness, and consistency of patient reviews, ultimately reducing the impact of asthma and COPD exacerbations on both patients and the NHS.

MISSON项目代表了英国最大规模的LungHealth软件区域实施。其主要目标是评估该技术是否可以提高患者评估的质量，有效性和一致性，最终减少哮喘和COPD恶化对患者和NHS的影响。

Preliminary estimates suggest that NHS England could achieve savings of up to £65.6 million in the first year, assuming comprehensive adoption of the LungHealth software across all practices, which involves a £30.9 million investment. Data collected from this collaborative project will be instrumental in informing NHS decision-making regarding the long-term adoption of technology to support respiratory reviews..

初步估计表明，假设在所有实践中全面采用LungHealth软件（涉及3090万英镑的投资），英格兰国家医疗服务体系（NHS England）在第一年可以节省多达6560万英镑。从这个合作项目收集的数据将有助于为NHS决策提供长期采用技术支持呼吸系统检查的信息。。

The MISSON initiative addresses critical gaps in the management of asthma and COPD, with over five million people in the UK living with asthma and 1.4 million with COPD. Guidelines recommend that respiratory patients receive reviews at least once every 12 months due to the significant morbidity and mortality rates associated with these conditions.

MISSON倡议解决了哮喘和COPD管理方面的关键差距，英国有500多万人患有哮喘，140万人患有COPD。指南建议呼吸系统患者至少每12个月接受一次检查，因为与这些疾病相关的发病率和死亡率很高。

However, it is estimated that only 30% of people with asthma and fewer than 20% of those with COPD in the UK receive even basic levels of care. This shortfall includes delays in diagnosis, misdiagnoses, inadequate disease management, and a lack of medical guidance and support. Greater Manchester, in particular, faces high prevalence rates of asthma and COPD, with emergency hospital admissions 30% higher than the national average..

然而，据估计，在英国，只有30%的哮喘患者和不到20%的COPD患者接受了甚至是基本水平的护理。这种不足包括诊断延误、误诊、疾病管理不足以及缺乏医疗指导和支持。特别是大曼彻斯特，哮喘和COPD的患病率很高，急诊住院率比全国平均水平高30%。。

Ralph Blom, General Manager of Chiesi UK and Ireland, remarked, “At Chiesi, we’re dedicated to improving patient outcomes through innovative solutions that support healthcare professionals and enhance patient care. This partnership is integral to delivering better care for people with respiratory diseases, easing healthcare workloads, and addressing the unmet needs of our local communities.

Chiesi UK and Ireland总经理拉尔夫·布洛姆（RalphBlom）表示：“在Chiesi，我们致力于通过支持医疗保健专业人员和加强患者护理的创新解决方案来改善患者的预后。这种伙伴关系对于为呼吸系统疾病患者提供更好的护理，减轻医疗保健工作量以及解决当地社区未满足的需求至关重要。

We’re excited to see the positive impact it can have.”.

我们很高兴看到它能产生积极的影响。”。

LungHealth software assists healthcare professionals in conducting high-quality and consistent reviews that align with national and international standards. It promotes effective history-taking and offers prompts for guideline-based treatment interventions, regardless of the clinician’s expertise. The technology features a comprehensive data dashboard for tracking outputs and can be utilized both remotely and in person to guide appropriate actions during annual reviews.

LungHealth软件帮助医疗保健专业人员进行符合国家和国际标准的高质量和一致的审查。它促进了有效的病史记录，并为基于指南的治疗干预提供了提示，无论临床医生的专业知识如何。这项技术的特点是有一个全面的数据仪表盘，用于跟踪产出，可以远程和亲自使用，以指导年度审查期间的适当行动。

Importantly, it involves patients in decision-making at every stage, ensuring they remain engaged in managing their condition. The software also provides information about community support services, such as pulmonary rehabilitation and smoking cessation, while offering clinical prompts to upskill healthcare professionals for the future.

重要的是，它让患者在每个阶段都参与决策，确保他们继续参与管理自己的病情。该软件还提供有关社区支持服务的信息，如肺康复和戒烟，同时为未来提高医疗保健专业人员的技能提供临床提示。

Overall, the technology aims to streamline patient care and alleviate the burden on healthcare providers by improving review efficiency. Additionally, it supports the NHS’s green agenda by striving to reduce carbon-heavy hospital admissions related to asthma and COPD exacerbations..

总体而言，该技术旨在通过提高审查效率来简化患者护理并减轻医疗保健提供者的负担。此外，它支持NHS的绿色议程，努力减少与哮喘和COPD恶化相关的高碳住院人数。。

Dr. Tracey Vell, Medical Director of Health Innovation Manchester, stated, “We hope that our collaboration with Chiesi will lead to significantly improved outcomes for our asthma and COPD patients in Greater Manchester, demonstrating the role technology can play in addressing health challenges. The software will facilitate clinical reviews for busy GP practices and ensure that patients receive optimal care.

曼彻斯特健康创新医学总监Tracey Vell博士表示：“我们希望与Chiesi的合作将显著改善大曼彻斯特哮喘和COPD患者的预后，展示技术在应对健康挑战方面的作用。该软件将有助于对繁忙的全科医生实践进行临床评估，并确保患者获得最佳护理。

The implementation of the LungHealth software will enable more efficient reviews in accordance with the latest guidance, alleviating the burden on Primary Care while providing better care for patients.”.

LungHealth软件的实施将根据最新指南进行更有效的审查，减轻初级保健的负担，同时为患者提供更好的护理。”。

The MISSON project is a collaborative effort between Chiesi UK and Ireland and Health Innovation Manchester, with LungHealth being delivered as part of this initiative by National Services for Health Improvement.

米森项目是基耶西英国和爱尔兰与曼彻斯特健康创新公司的合作项目，伦盖尔特作为该项目的一部分由National Services for Health Improvement提供。